GLP-1 receptor agonists have transformed the landscape of weight management for many individuals.
According to insights from Goldman Sachs Research, the global market for antiobesity medications (AOMs) is projected to reach a staggering $100 billion by 2030.1
This remarkable growth offers an unparalleled opportunity for food, beverage and dietary supplement manufacturers to tackle the unique challenges faced by consumers who are actively using these treatments or transitioning away from them.
All of this comes at a time when, according to the World Health Organization, 30% of the global population is overweight and, of these consumers, 60% of seek weight control.2
The rising availability of GLP-1 receptor agonists to consumers in various regions enables new avenues for them to reach their goals. However, there are pivotal needs that must be addressed.
Extensive consumer and market research conducted by ADM on the largest current demographic for GLP-1 medication use — United States consumers — has pinpointed how consumption habits change for those engaging with GLP-1 treatments and the nutritional needs that come with that.3
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.